Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  title={Incorporation of bevacizumab in the primary treatment of ovarian cancer.},
  author={Robert Allen Burger and Mark F. Brady and Michael A. Bookman and Gini F. Fleming and Bradley J. Monk and Helen Q. Huang and Robert S. Mannel and Howard D. Homesley and Jeffrey M. Fowler and Benjamin Greer and Matthew P. Boente and Michael J. Birrer and Sharon X. Liang},
  journal={The New England journal of medicine},
  volume={365 26},
BACKGROUND Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of bevacizumab to standard front-line therapy. METHODS In our double-blind, placebo-controlled, phase 3 trial, we randomly assigned eligible patients with newly diagnosed… 

Figures and Tables from this paper

A phase 3 trial of bevacizumab in ovarian cancer.

In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.

Bevacizumab and ovarian cancer

This review summarizes the activity and toxicity of bevacizumab in the treatment of ovarian cancer, both as single-agent drug and in combination with cytotoxic chemotherapy.

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

A systematic literature review found significant efficacy gains were achieved with the addition of bevacizumab to standard chemotherapy in four randomized, double-blind, phase III trials, both as front-line treatment and in patients with recurrent disease.

Bevacizumab in the Treatment of Ovarian Cancer

Clinical trial data on bevacizumab in the treatment of ovarian cancer is presented and the indication and pitfalls in the application of bevazicumab in patients with this malignancy are discussed.

Critical appraisal of bevacizumab in the treatment of ovarian cancer

The clinical trial results with bevacizumab have supported its recent approval in Europe and the United States as a treatment for ovarian cancer and selection of patients for personalized treatment is described.

The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer

The addition of bevacizumab to standard cytotoxic chemotherapy regimens has demonstrated improved response rates, and improved progression free survival, and this results have stimulated research in additional angiogenesis inhibitors and trials to further incorporate beVacIZumab into the treatment schema for patients with recurrent ovarian cancer.

Bevacizumab Combination Therapy

Bevacizumab combination therapy had generally acceptable tolerability in these studies, with the nature of adverse events generally similar to that observed in previous clinical trials in patients with other solid tumours.

The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects

Based on the available evidence, a higher dosage and a longer duration of bevacizumab appear to achieve better therapeutic effects and progression-free survival and, on the other hand, patients with more severe diseases or at a higher risk of progression seem to benefit more from bevazquezumab use.

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.

Angiogenesis plays a fundamental role in the pathogenesis of ovarian cancer. Vascular endothelial growth factor (VEGF) expression has been associated with the development of malignant ascites and

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Bvacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with EOC/PPC and merits phase III investigation.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Bvacizumab has single-agent activity in patients with platinum-resistant EOC or PSC and a higher than expected incidence of GIP was noted in these heavily pretreated patients.

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

Safety pharmacology studies with bevacizumab in cynomolgus monkeys showed that this agent is generally well tolerated with no unexpected adverse events, implying that the most effective use of anti-VEGF therapy is in combination with chemotherapy.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

  • C. AghajanianS. Blank L. Nycum
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
GC plus BV followed by BV until progression resulted in a statistically significant improvement in PFS compared with GC plus PL in platinum-sensitive ROC, and the primary end point was progression-free survival by RECIST.

Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?

The small percentage of tumors with high levels of VEGF activity suggests that the role of bevacizumab may potentially be limited to a few patients; these patients could be targeted by molecular profiling.

OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).

Results show a statistically significant and clinically relevant benefit when bevacizumab is added to chemotherapy in patients with recurrent, platinum sensitive EOC, PPC, and FTC.

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

It was found that longer exposure to anti-VEGF monoclonal antibodies delayed tumor growth and extended survival in established tumors from both cell transplants and genetic tumor models and prevented regrowth of a subset of residual tumors following cytoablative therapy.

The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

The data suggest that the degree of neovascularization may have prognostic significance in epithelial ovarian carcinoma, especially for women with early-stage disease, and may allow the selection of women at high risk for recurrence who may benefit from aggressive adjuvant therapy.

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.

  • A. ByrneLeorah H. Ross R. Jaffe
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
Systemic administration of the V EGF-Trap, a recently described high-affinity soluble decoy receptor for VEGF, prevents ascites accumulation and also inhibits the growth of disseminated cancer.